ApprovedWeight lossSubcutaneousEvidence 5/5

Exenatide

Also known as: Byetta, Bydureon, exendin-4

Exenatide activates the GLP-1 receptor to increase glucose-dependent insulin secretion, suppress inappropriate glucagon release, and slow gastric emptying.

Read guide Buy / compare source

Exenatide

Drug class: GLP-1 receptor agonist (incretin mimetic)
Primary targets: GLP-1 receptor
Dose reference: Reference label doses (not recommendations): Byetta 5-10 mcg subcutaneously twice daily before meals; Bydureon BCise 2 mg subcutaneously once weekly
Half-life: Approximately 2.4 hours for immediate-release Byetta; extended-release (Bydureon BCise) microspheres release over weeks and exenatide can persist about 10 weeks after the last dose
Developer / origin: Discovered as exendin-4 by John Eng at a VA Medical Center; developed by Amylin Pharmaceuticals with Eli Lilly, later held by AstraZeneca
Reference year: 2005
Evidence score: 5/5 - Approved drug, strong clinical evidence

Evidence 5/5

Approved drug, strong clinical evidence

Exenatide is the first FDA-approved GLP-1 receptor agonist, supported by phase 3 glycemic trials in type 2 diabetes and the large EXSCEL cardiovascular outcomes trial, which showed cardiovascular safety (noninferiority) but not statistically significant superiority. It is approved for glycemic control, not as a weight-loss drug, though weight reduction is a commonly observed secondary effect.

Approved medication with substantial human clinical evidence.

Evidence basis

FDA-approved prescribing information for Byetta (immediate-release, approved 2005) and Bydureon BCise (extended-release, weekly)
EXSCEL randomized controlled trial of 14,752 patients (NEJM 2017): MACE 11.4% exenatide vs 12.2% placebo, noninferior, p=0.06 for superiority
Original exendin-4 isolation and characterization from Heloderma suspectum venom (Eng et al., J Biol Chem 1992)
Approved indication is type 2 diabetes glycemic control; weight loss is not an approved indication

Key references

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.